Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
486.43
+0.78 (0.16%)
Jul 20, 2026, 12:22 PM EDT - Market open

Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 30 analysts polled by S&P Global, Vertex Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $556.24. The average 1-year stock price forecast is 14.35% higher than the current stock price, while the lowest is $350 (-28.05%) and the highest is $641 (+31.78%).

Price Target: $556.24 (+14.35%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$350$556.24$572$641
Change-28.05%+14.35%+17.59%+31.78%

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy212221212120
Buy455664
Hold545544
Sell110011
Strong Sell111111
Total323332333330

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Citi
Citi
Buy
Maintains
$585
BuyMaintains$585+20.26%Jul 16, 2026
UBS
UBS
Buy
Reiterates
$545$585
BuyReiterates$545$585+20.26%Jul 13, 2026
Truist Financial
Truist Financial
Buy
Maintains
$542$560
BuyMaintains$542$560+15.12%Jul 13, 2026
BMO Capital
BMO Capital
Buy
Maintains
$600
BuyMaintains$600+23.35%Jul 13, 2026
Wells Fargo
Wells Fargo
Buy
Reiterates
$550
BuyReiterates$550+13.07%Jul 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
13.05B
from 12.00B
Increased by 8.71%
Revenue Next Year
14.34B
from 13.05B
Increased by 9.95%
EPS This Year
18.96
from 18.40
Increased by 3.06%
EPS Next Year
21.41
from 18.96
Increased by 12.91%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
7.57B8.93B9.87B11.02B12.00B13.05B
Revenue Growth
22.06%17.91%10.51%11.66%8.90%8.71%
Operating Income
3.89B4.38B4.31B4.40B4.69B5.53B
Net Income
2.34B3.32B3.62B-535.60M3.95B4.52B
EPS
----18.4018.96
EPS Growth
----4,280.95%3.06%
Forward PE
16.4218.8324.4422.6622.6125.65
Free Cash Flow
2.40B3.31B3.51B2.80B2.57B4.95B
No. Analysts
-----21
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High13.1B
Avg13.0B
Low13.0B

Revenue Growth

Revenue Growth202620272028
High
9.4%
Avg
8.7%
Low
7.9%

EPS Forecast

EPS202620272028
High19.85
Avg18.96
Low17.61

EPS Growth

EPS Growth202620272028
High
7.9%
Avg
3.1%
Low
-4.3%